alkermes.com (ALKS) Earnings growth forecast for next year

ALKS (alkermes.com) - company brandmark

Alkermes plc (ALKS) maintains a high reputation in the therapy of complex mental pathologies. The company's forward EPS dynamics model reflects current market expectations, with the latest value recorded as 209.00. However, generics and the risk of patent expiration are creating pressure. Intensive R&D processes and the launch of new treatments for schizophrenia serve as positive drivers.

Alkermes PLC (ALKS): Expected net earnings per share growth next year from 07/04/2022 to 11/12/2026

Comprehensive metric breakdowns and analytics for alkermes.com (ALKS)

- share price and consensus valuation forecast:
Stock Price Alkermes Inc.|ALKS - Consensus Target
- market capitalization details:
Market Capitalization Alkermes|ALKS - Value Adjusted for Debt and Cash
- book capitalization indicators:
Net Assets per Single Share Alkermes|ALKS - Total Stockholders' Equity|Market Capitalization to Book Value Ratio alkermes.com|ALKS - Company Total Assets
- company total debt and liquidity indicators:
Debt to Equity Alkermes plc|ALKS - Long-Term Debt to Equity|Short-Term Debt to Equity Alkermes|ALKS - Company Aggregate Debts|Debts to Book Capitalization Alkermes|ALKS - Long-Term Debt|Company Short-Term Debt Alkermes|Quick Liquidity alkermes.com
- net income and valuation ratios data:
ALKS - Net Income|Projected Future Earnings Alkermes plc|ALKS - Market Cap to Earnings|Future Price to Earnings Alkermes plc|ALKS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Alkermes|ALKS - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Alkermes|ALKS - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months alkermes.com|ALKS - Earnings per share growth in current year|Earnings growth forecast for next year Alkermes plc
Basic company analysis:Alkermes Inc., ALKS
Core merchandise of Alkermes

Steady demand for addiction and schizophrenia treatments makes Alkermes plc (ALKS) cash flows predictable, which is directly reflected in the projected EPS growth rate for next year. This metric measures the expected change in earnings per share, allowing investors to distinguish systemic business growth from one-off factors and avoid overpaying for inflated analyst expectations when assessing the asset's fundamental value.

Competitors of Alkermes plc

AVDL (Avadel Pharma) - Earnings growth forecast for next year|Expected earnings per share growth for next year atai (ATAI)|Earnings growth forecast for next year GHRS|MNMD (mindmed.co) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year COMPASS Pathways CMPS|LB Pharmaceuticals, Inc. (LBRX) - Expected net earnings per share growth next year|Bright Minds Biosciences Inc - Earnings growth forecast for next year|VNDA - Earnings growth forecast for next year|cybin.com (CYBN) - Net earnings per share growth forecast for next year|ANRO (altoneuroscience.com) - Net earnings per share growth forecast for next year|Net earnings per share growth forecast for next year NRx Pharmaceuticals, Inc.|Earnings growth forecast for next year Cingulate Corp|Earnings growth forecast for next year SILO|CPHI - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Clearmind Medicine CMND|Expected earnings per share trend next year PBM|SPRC - Net earnings per share growth forecast for next year|Seelos Therapeutics Inc. (SEEL) - Expected earnings per share growth for next year|VRPX: Earnings growth forecast for next year|Expected net earnings per share growth next year Karuna Pharma (KRTX)